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The role of immunological mechanisms in controlling the
growth of malignant tumours is controversial (Underwood,
1974) and, in the case of the common human malignancies,
the evidence is slight. It is well recognised, however, that in
breast cancer in particular there can be a long disease-free
interval terminating in late recurrence, suggesting that
important tumour-host interactions influence tumour growth
kinetics. The frequent presence of an infiltrate of mono-
nuclear cells in primary breast carcinomas has been taken as
evidence of a host defence mechanism and in several studies
the intensity of this putative response has been positively
correlated with good prognosis (Hamlin, 1968; Bloom et al.,
1970). Some 75% of the leucocytes in primary breast
carcinomas are T-lymphocytes (Whitwell et al., 1984); their
function in this site is unknown but may be either a non-
specific reaction to tumour necrosis or a more complex
response to malignant cells.
The peripheral blood lymphocyte count has also been
reported to have a positive association with 5 year survival
and disease-free survival rates (Papatestas et al., 1976).
Immune competence, measured by a summary score derived
from in vitro lymphocyte function tests and in vivo cutaneous
reactivity, has been related to prognosis though in this study
the peripheral lymphocyte count was not found to have
prognostic value (Adler et al., 1980). However, a subsequent
large investigation of potential prognostic factors in operable
breast cancer indicated that a pre-operative blood lympho-
cyte count of 1.5 x 1091 1 or less is predictive of early
recurrence (Ownby et al., 1983). We have tested this
hypothesis in a retrospective study of a consecutive series of
women undergoing mastectomy and have sought to define
further the relationships between peripheral blood lympho-
cyte count, nodal involvement, tumour size and disease-free
interval.
The study group consisted of 308 women with confirmed
carcinoma of the breast who underwent mastectomy at Selly
Oak Hospital between January 1978 and December 1982. All
were judged on clinical grounds to have local disease only.
Peripheral lymphocyte count was recorded pre-operatively.
Node status was ascertained pathologically by routine
axillary node sampling in 248 patients; the node status was
considered to be unknown in the remainder for statistical
analysis. Tumour size was measured from the surgically
resected specimen in 285 cases and was unrecorded in the
remaining 23 patients. Simple mastectomy was performed in
all patients and clinical follow-up was undertaken according
to a standard protocol. Patients were reviewed routinely
every 3 months for 18 months after operation and then every
6 months indefinitely. Further investigations were under-
taken if history or examination suggested recurrent disease,
either at a scheduled review or at re-referral between such
reviews.
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The interrelation of variables other than survival was
studied by conventional parametric tests and linear
regression. Survival analysis was performed by the product-
limit method using Breslow's generalisation of the Wilcoxon
test for group contrasts (Breslow, 1970). For the 216 cases
with complete data, the proportional hazards model (Cox,
1972) was used to examine the effects of multiple factors on
time to relapse; validity of the proportionality assumption
was confirmed by inspection of log minus log plots and
goodness of fit assessed by plotting the cumulative hazard
function of residuals.
There was no difference in pre-operative peripheral
lymphocyte counts (PLC) between those women found to
have nodal involvement and those with tumour-free nodes
(mean +s.d. 2.13+1.04 and 2.28+1.35x 10l9-', P>0.3).
PLC was not associated with tumour size or with age of the
patient. As might be predicted, tumour size was significantly
greater in node-positive women (4.18 +2.18cm) than in
node-negative women (3.13 +2.17cm, P<0.0005).
The prior hypothesis that PLC less than 1.5 x 1091-I is
predictive of relapse was initially tested and supported by
our data (Figure 1). Disease-free survival was significantly
worse in this group (P<0.05). The data were then explored
to clarify the form of the relationship. It was observed that
the adverse prognostic significance of low PLC was confined
to a subgroup with PLC less than or equal to 1.0 x I 0 1-
(P<0.01); this group's survival is compared with that of
other strata in Figure 2. In the proportional hazards model
the prognostic importance of both node status (P<0.001)
and tumour size (P<0.001) was confirmed and PLC (di-
chotomized around 1.0 x 1091 -1) contributed significantly to
the model incorporating these two variables (P<0.05).
Neither age nor menopausal status were associated with
recurrence hazard.
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Figure 1 Cumulative disease-free survival for patients with pre-
operative peripheral lymphocyte counts (A) less than, and (B)
equal to or greater than, I.5x 1091- (n =89 and 219
respectively).
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Figure 2 Cumulative disease-free survival by pre-operative
lymphocyte count: (A) l.Ox 1091-' or less; (B) 1.1-2.0x 1091-1;
(C) 2.1-3.5xl091-; (D) greater than 3.5x 1091-l (n=21, 143,
1 13 and 31 respectively).
There was no association by x2 between node involvement
(positive, negative) and the finding of marked lymphopenia
(<l.Ox 1091-l) (P>0.5).
The estimates of median interval to recurrence, which
must be viewed as approximate only, were 18 months (s.e. 7
months) for the group with PLC <1.0x 1091-1, and 51
months (s.e. 12 months) for the group with PLC> 1.0 x
1091 1.
The initial analysis tested the prior hypothesis that
lymphocyte counts of 1.5 x 1091-1 or less was associated
with increased relapse rate (Ownby et al., 1983), and our
data provide strong supportive evidence of this. The identifi-
cation of the subgroup with PLC < 1.0 x 1091-l as being
particularly at risk was achieved by retrospective subgroup
analysis and inferences must be correspondingly more
tentative. However, the uniformity of relapse rates among
subgroups of women with PLC> 1.0 x 1091-1 is striking and
gives no support for the alternative hypothesis that there is a
continuous inverse relationship between PLC and relapse
hazard.
The question then arises whether low PLC is causally
related to increased relapse hazard, or merely a secondary
phenomenon in the presence of extensive occult disease. The
latter seems unlikely in view of the absence of any
association between PLC and the presence or absence of
tumour deposits in axillary nodes, or between PLC and
tumour size. In either case, pre-operative PLC might be
useful empirically to identify prognostic groups. PLC is an
easily measured host factor which could be used in
conjunction with tumour-related variables such as
histological grade, stage and tumour size to define a group
of patients at risk of early recurrence who might benefit
from adjuvant therapy. If it be the case that lymphopenia
has a direct causal link with accelerated tumour progression,
however, the use of cytotoxic agents which deplete the
circulating lymphocyte population would be inadvisable.
Cyclophosphamide, for instance, which is commonly
incorporated in combination regimes for breast cancer, has
such an effect (Feehally et al., 1984). The possibility of
mutually antagonistic actions on micrometastatic disease and
on a lymphocyte-mediated tumour inhibitory mechanism has
to be considered, especially in view of the currently uncertain
role of adjuvant chemotherapy (Mourisden & Palshof, 1983).
It would clearly be of great interest to establish whether
the lymphopenia associated with high recurrence rate is due
to a deficiency of one particular sub-population of lympho-
cytes or a general depletion of the circulating lymphocyte
pool. This could be investigated using available cell market
methods and should be the basis for a further prospective
study.
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